Cargando…

FGF7/FGFR2–JunB signalling counteracts the effect of progesterone in luminal breast cancer

We have recently demonstrated that fibroblast growth factor receptor 2 (FGFR2)‐mediated signalling alters progesterone receptor (PR) activity and response of oestrogen receptor α (ER)‐positive (ER+) breast cancer (BCa) cell lines to anti‐ER agents. Little is known about whether the crosstalk between...

Descripción completa

Detalles Bibliográficos
Autores principales: Mieczkowski, Kamil, Kitowska, Kamila, Braun, Marcin, Galikowska‐Bogut, Barbara, Gorska‐Arcisz, Monika, Piasecka, Dominika, Stawiski, Konrad, Zaczek, Anna J., Nejc, Dariusz, Kordek, Radzisław, Romanska, Hanna M., Sadej, Rafal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348598/
https://www.ncbi.nlm.nih.gov/pubmed/35726195
http://dx.doi.org/10.1002/1878-0261.13274
_version_ 1784761949557358592
author Mieczkowski, Kamil
Kitowska, Kamila
Braun, Marcin
Galikowska‐Bogut, Barbara
Gorska‐Arcisz, Monika
Piasecka, Dominika
Stawiski, Konrad
Zaczek, Anna J.
Nejc, Dariusz
Kordek, Radzisław
Romanska, Hanna M.
Sadej, Rafal
author_facet Mieczkowski, Kamil
Kitowska, Kamila
Braun, Marcin
Galikowska‐Bogut, Barbara
Gorska‐Arcisz, Monika
Piasecka, Dominika
Stawiski, Konrad
Zaczek, Anna J.
Nejc, Dariusz
Kordek, Radzisław
Romanska, Hanna M.
Sadej, Rafal
author_sort Mieczkowski, Kamil
collection PubMed
description We have recently demonstrated that fibroblast growth factor receptor 2 (FGFR2)‐mediated signalling alters progesterone receptor (PR) activity and response of oestrogen receptor α (ER)‐positive (ER+) breast cancer (BCa) cell lines to anti‐ER agents. Little is known about whether the crosstalk between ER and PR, shown to be modulated by the hormonal background, might also be affected by FGFR2. Here, PR‐dependent behaviour of ER+ BCa cells was studied in the presence of oestrogen (E2) and progesterone (P4) and/or FGF7. In vitro analyses showed that FGF7/FGFR2 signalling: (a) abolished the effect of P4 on E2‐promoted 3D cell growth and response to tamoxifen; (b) regulated ER and PR expression and activity; (c) increased formation of ER–PR complexes; and (d) reversed P4‐triggered deregulation of ER‐dependent genes. Analysis of clinical data demonstrated that the prognostic value of FGFR2 varied between patients with different menopausal status; that is, high expression of FGFR2 was significantly associated with longer progression‐free survival (PFS) in postmenopausal patients, whereas there was no significant association in premenopausal patients. FGFR2 was found to positively correlate with the expression of JunB proto‐oncogene, AP‐1 transcription factor subunit (JUNB), an ER‐dependent gene, only in premenopausal patients. Molecular analyses revealed that the presence of JunB was a prerequisite for FGFR2‐mediated abrogation of P4‐induced inhibition of cell growth. Our results demonstrate for the first time that the FGF7/FGFR2–JunB axis abolishes the modulatory effects of PR on ER‐associated biological functions in premenopausal ER+ BCa. This may provide foundations for a better selection of patients for FGFR‐targeting therapeutic strategies.
format Online
Article
Text
id pubmed-9348598
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93485982022-08-05 FGF7/FGFR2–JunB signalling counteracts the effect of progesterone in luminal breast cancer Mieczkowski, Kamil Kitowska, Kamila Braun, Marcin Galikowska‐Bogut, Barbara Gorska‐Arcisz, Monika Piasecka, Dominika Stawiski, Konrad Zaczek, Anna J. Nejc, Dariusz Kordek, Radzisław Romanska, Hanna M. Sadej, Rafal Mol Oncol Research Articles We have recently demonstrated that fibroblast growth factor receptor 2 (FGFR2)‐mediated signalling alters progesterone receptor (PR) activity and response of oestrogen receptor α (ER)‐positive (ER+) breast cancer (BCa) cell lines to anti‐ER agents. Little is known about whether the crosstalk between ER and PR, shown to be modulated by the hormonal background, might also be affected by FGFR2. Here, PR‐dependent behaviour of ER+ BCa cells was studied in the presence of oestrogen (E2) and progesterone (P4) and/or FGF7. In vitro analyses showed that FGF7/FGFR2 signalling: (a) abolished the effect of P4 on E2‐promoted 3D cell growth and response to tamoxifen; (b) regulated ER and PR expression and activity; (c) increased formation of ER–PR complexes; and (d) reversed P4‐triggered deregulation of ER‐dependent genes. Analysis of clinical data demonstrated that the prognostic value of FGFR2 varied between patients with different menopausal status; that is, high expression of FGFR2 was significantly associated with longer progression‐free survival (PFS) in postmenopausal patients, whereas there was no significant association in premenopausal patients. FGFR2 was found to positively correlate with the expression of JunB proto‐oncogene, AP‐1 transcription factor subunit (JUNB), an ER‐dependent gene, only in premenopausal patients. Molecular analyses revealed that the presence of JunB was a prerequisite for FGFR2‐mediated abrogation of P4‐induced inhibition of cell growth. Our results demonstrate for the first time that the FGF7/FGFR2–JunB axis abolishes the modulatory effects of PR on ER‐associated biological functions in premenopausal ER+ BCa. This may provide foundations for a better selection of patients for FGFR‐targeting therapeutic strategies. John Wiley and Sons Inc. 2022-07-04 2022-08 /pmc/articles/PMC9348598/ /pubmed/35726195 http://dx.doi.org/10.1002/1878-0261.13274 Text en © 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Mieczkowski, Kamil
Kitowska, Kamila
Braun, Marcin
Galikowska‐Bogut, Barbara
Gorska‐Arcisz, Monika
Piasecka, Dominika
Stawiski, Konrad
Zaczek, Anna J.
Nejc, Dariusz
Kordek, Radzisław
Romanska, Hanna M.
Sadej, Rafal
FGF7/FGFR2–JunB signalling counteracts the effect of progesterone in luminal breast cancer
title FGF7/FGFR2–JunB signalling counteracts the effect of progesterone in luminal breast cancer
title_full FGF7/FGFR2–JunB signalling counteracts the effect of progesterone in luminal breast cancer
title_fullStr FGF7/FGFR2–JunB signalling counteracts the effect of progesterone in luminal breast cancer
title_full_unstemmed FGF7/FGFR2–JunB signalling counteracts the effect of progesterone in luminal breast cancer
title_short FGF7/FGFR2–JunB signalling counteracts the effect of progesterone in luminal breast cancer
title_sort fgf7/fgfr2–junb signalling counteracts the effect of progesterone in luminal breast cancer
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348598/
https://www.ncbi.nlm.nih.gov/pubmed/35726195
http://dx.doi.org/10.1002/1878-0261.13274
work_keys_str_mv AT mieczkowskikamil fgf7fgfr2junbsignallingcounteractstheeffectofprogesteroneinluminalbreastcancer
AT kitowskakamila fgf7fgfr2junbsignallingcounteractstheeffectofprogesteroneinluminalbreastcancer
AT braunmarcin fgf7fgfr2junbsignallingcounteractstheeffectofprogesteroneinluminalbreastcancer
AT galikowskabogutbarbara fgf7fgfr2junbsignallingcounteractstheeffectofprogesteroneinluminalbreastcancer
AT gorskaarciszmonika fgf7fgfr2junbsignallingcounteractstheeffectofprogesteroneinluminalbreastcancer
AT piaseckadominika fgf7fgfr2junbsignallingcounteractstheeffectofprogesteroneinluminalbreastcancer
AT stawiskikonrad fgf7fgfr2junbsignallingcounteractstheeffectofprogesteroneinluminalbreastcancer
AT zaczekannaj fgf7fgfr2junbsignallingcounteractstheeffectofprogesteroneinluminalbreastcancer
AT nejcdariusz fgf7fgfr2junbsignallingcounteractstheeffectofprogesteroneinluminalbreastcancer
AT kordekradzisław fgf7fgfr2junbsignallingcounteractstheeffectofprogesteroneinluminalbreastcancer
AT romanskahannam fgf7fgfr2junbsignallingcounteractstheeffectofprogesteroneinluminalbreastcancer
AT sadejrafal fgf7fgfr2junbsignallingcounteractstheeffectofprogesteroneinluminalbreastcancer